Quick summary
Follistatin-344 is a naturally occurring glycoprotein that potently inhibits myostatin and activin A, creating conditions for dramatic muscle growth. While AAV gene therapy trials showed muscle gains in dystrophy patients, injectable use carries documented ocular risks including retinal detachment.
Overview
Follistatin-344 is the 344-amino acid isoform of follistatin, a naturally occurring glycoprotein that potently inhibits myostatin and activin A — two TGF-β superfamily members that limit muscle growth. By blocking these inhibitory signals, Follistatin-344 creates conditions for dramatic increases in lean muscle mass. It has been studied via AAV-mediated gene therapy in clinical settings and as a recombinant peptide in preclinical research. Human data is extremely limited and no injectable follistatin protocol has been validated in clinical trials.
Mechanism of action
Follistatin-344 is a secreted glycoprotein that acts as a high-affinity binding protein and functional antagonist of myostatin (GDF-8) and activin A, both of which are members of the TGF-β superfamily. By binding these ligands extracellularly, follistatin prevents them from engaging their type I/II serine-threonine kinase receptors (ActRIIA/B, ALK4/5), thereby blocking the downstream SMAD2/3 signaling cascade that restricts muscle fiber hypertrophy and promotes atrophy. The resulting disinhibition of mTOR and satellite cell activation drives both hypertrophy of existing fibers and hyperplasia via myoblast proliferation. The 27-amino acid C-terminal extension unique to FS-344 enhances heparan sulfate proteoglycan binding on cell surfaces, prolonging local tissue retention versus the shorter FS-315 isoform. Follistatin also suppresses activin-driven FSH secretion from the pituitary, with significant reproductive endocrine consequences.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| Muscle growth / myostatin inhibition (community research protocol) | subcutaneous | 50–200 mcg | daily for 10-30 days, then cycle off | No validated human protocol. Common community reports range 50-100 mcg/day for 10 days to 100-200 mcg 2-3x weekly. Highly experimental with documented ocular risks. |
| Pre-workout (community pulse dosing) | intramuscular | 50–100 mcg | training days only | Inject 30 minutes pre-workout into target muscle group. No clinical validation. WADA prohibited. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Most human evidence comes from a gene therapy trial using AAV1-FS344 in Becker muscular dystrophy and inclusion body myositis patients, which demonstrated increased muscle volume and strength over 2 years without serious adverse events. Preclinical data in mice, primates, and dogs consistently shows marked increases in muscle mass (2-3x) with myostatin inhibition. No injectable recombinant follistatin-344 peptide human trials exist — all community protocols are extrapolated from animal data or gene therapy studies. A 2020 case series documented 11 male bodybuilders who developed central serous chorioretinopathy (CSCR, a retinal condition) following subcutaneous follistatin-344 injections, suggesting real ocular risk. FSH suppression (up to 75% reduction within one week in animal models) raises fertility concerns.[1][2][3][4]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Follistatin-344 for synergistic effects.
Legal status
Research chemical only. No FDA-approved follistatin therapeutic exists for muscle enhancement. The gene therapy application (AAV1-FS344) is under research IND. Injectable peptide forms are sold by research chemical suppliers but have no clinical validation. WADA prohibits follistatin and related myostatin inhibitors in competitive sports.
Sourcing & access
Research compound
Follistatin-344 is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
Follistatin-344 is the 344-amino acid isoform of follistatin, a glycoprotein that blocks myostatin and activin A, two TGF-beta superfamily members that limit muscle growth. Its unique 27-amino acid C-terminal extension enhances tissue retention versus the shorter FS-315 isoform.
Follistatin-344 binds myostatin and activin A extracellularly, preventing them from activating SMAD2/3 signaling that restricts muscle growth. This disinhibition of mTOR and satellite cell activation drives both fiber hypertrophy and hyperplasia. It also suppresses activin-driven FSH secretion from the pituitary.
Documented risks include central serous chorioretinopathy (CSCR, retinal detachment documented in 11 bodybuilders), FSH suppression up to 75% causing fertility disruption, tendon injury from muscle growth outpacing connective tissue, and hormonal dysregulation. No injectable human trials exist.
A 2020 case series documented 11 male bodybuilders who developed central serous chorioretinopathy (CSCR), a retinal condition, following subcutaneous follistatin-344 injections. This represents a real and documented ocular risk that is unique among peptides.
Research references
- Inhibition of myostatin with emphasis on follistatin as a therapy for muscle diseaseReview
- Follistatin gene delivery enhances muscle growth and strength in nonhuman primatesPubMed
- Follistatin complexes Myostatin and antagonises Myostatin-mediated inhibition of myogenesisPubMed
- Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx micePubMed